[1]高灵利 李延红 李凤仙 蒋令修 李晓晖.丹参多酚酸联合双联抗血小板聚集药物对CYP2C19基因变异的颅内外动脉支架成形术后患者的影响[J].卒中与神经疾病杂志,2019,26(02):206-208.[doi:10.3969/j.issn.1007-0478.2019.02.018]
　Gao Lingli,Li Yanhong,Li Fengxian,et al.The effects of Danshen polyphenolic acid combined with dual antiplatelet drugs on patients with CYP2C19 gene mutation after intracranial and extracranial stenting[J].Stroke and Nervous Diseases,2019,26(02):206-208.[doi:10.3969/j.issn.1007-0478.2019.02.018]
点击复制

丹参多酚酸联合双联抗血小板聚集药物对CYP2C19基因变异的颅内外动脉支架成形术后患者的影响()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第26卷
期数:
2019年02期
页码:
206-208
栏目:
论 著
出版日期:
2019-04-20

文章信息/Info

Title:
The effects of Danshen polyphenolic acid combined with dual antiplatelet drugs on patients with CYP2C19 gene mutation after intracranial and extracranial stenting
文章编号:
1007-0478(2019)02-0206-04
作者:
高灵利 李延红 李凤仙 蒋令修 李晓晖
475001 河南省开封市河南大学第一附属医院全科医学科(高灵利 李延红 李凤仙),神经内科(蒋令修 李晓晖)
Author(s):
Gao Lingli; Li Yanhong; Li Fengxian; et al.
Department of General Practice,The First Affiliated Hospital of Henan University,Kaifeng Henan 475001
关键词:
丹参多酚酸 双联抗血小板聚集药物 CYP2C19基因变异 颅内外动脉支架成形术
Keywords:
Salvia polyphenols Dual antiplatelet drugs CYP2C19 gene mutation Intracranial and extracranial stenting
分类号:
R543.4
DOI:
10.3969/j.issn.1007-0478.2019.02.018
文献标志码:
A
摘要:
目的 探讨丹参多酚酸联合双联抗血小板聚集药物对CYP2C19基因变异的颅内外动脉支架成形术后患者的影响。方法 研究对象选取于本院2015年7月-2018年3月进行颅内外动脉支架成形术合并CYP2C19基因变异患者102例,使用随机数字表法分为双联组(51例)及联合组(51例),双联组仅给予双联抗血小板聚集药物,联合组在其治疗基础上给予丹参多酚酸针剂,比较2组治疗前后氧化应激反应、血管内皮功能、血小板功能及治疗后不良事件发生率。结果 治疗前2组丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)、内皮素-1(ET-1)、血小板活化标志物(CD62p、 CD63)水平无显著差异(P>0.05)。治疗后联合组MDA、ET-1、CD62p及CD63水平显著低于双联组; SOD、NO水平显著高于双联组; 联合组不良事件发生率显著低于双联组(P<0.05)。结论 丹参多酚酸联合双联抗血小板聚集药物能有效降低CYP2C19基因变异的颅内外动脉支架成形术后患者氧化应激反应,改善其血管内皮功能及血小板功能,减少不良事件发生率。
Abstract:
ObjectiveTo investigate the effects of Danshen polyphenolic acid combined with dual antiplatelet drugs on patients with CYP2C19 gene mutation after intracranial and extracranial stenting.Methods A total of 102 patients with intracranial and extracranial stenting and CYP2C19 gene mutation were enrolled in our hospital from July 2015 to March 2018.The patients were randomly divided into two groups:the double group(51 cases)and the combination group(51 cases).The double group was given only dual antiplatelet drugs,and the combined group was given dual antiplatelet drugs and administration of salvianolate.The incidence of oxidative stress,vascular endothelial function,platelet function and adverse events after treatment were compared between the two groups.Results The levels of malondialdehyde(MDA),superoxide dismutase(SOD),nitric oxide(NO),endothelin-1(ET-1)and platelet activation markers(CD62p,CD63)were not detected before treatment,and there were not significant differences between two goups(P>0.05).The levels of MDA,ET-1,CD62p and CD63 in the combined group were significantly lower than those in the double group after treatment,the levels of SOD and NO were significantly higher than those in the double group,the incidence of adverse events in the combined group was significantly lower than that in the double group,and the differences were statistically significant(P<0.05).Conclusion Danshen polyphenolic acid combined with dual antiplatelet drugs could effectively reduce the oxidative stress response of patients with CYP2C19 gene mutation after intracranial and extracranial stenting,improve their vascular endothelial function and platelet function,and reduce the incidence of adverse events.

参考文献/References:

[1] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组,中华医学会神经病学分会神经血管介入协作组.中国缺血性脑血管病血管内介入诊疗指南2015[J].中华神经科杂志,2015,48(10):830-837.
[2] 刘海平,朱辉.药物与支架成形术治疗颅内外血管狭窄的疗效比较[J].神经疾病与精神卫生,2017,17(1):37-40.
[3] 刘晶,王玉琳,闫丽丽.双联抗血小板药物联合低分子肝素治疗进展性脑梗死的研究[J].山西医药杂志,2015,44(23):2772-2774.
[4] 唐杰,廖艳,李光勤,等.颅外颈动脉支架置入术后抗血小板聚集治疗的对比研究[J].卒中与神经疾病,2017,24(4):310-313.
[5] 刘浙波,夏豪,杨洋,等.氯吡格雷药物代谢相关基因CYP2C19多态性对冠心病PCI术后患者MACE的影响[J].中国心血管病研究,2016,14(6):1672-5301.
[6] 牟世伟,高金娥,刘颖.注射用丹参多酚酸盐治疗高龄冠心病心绞痛病人的临床疗效及对血脂、BNP、CRP的影响研究[J].内蒙古医科大学学报,2017,39(5):449-452.
[7] 谢湘桂,刘赫,贾建文,等.老年脑缺血患者颅内外动脉支架成形术后再狭窄分布研究[J].中华老年医学杂志,2015,34(7):748-750.
[8] 徐美桃,常燕飞,王悦喜.冠心苏合丸联合双联抗血小板药物防治PCI术后再狭窄的临床观察[J].中医药导报,2016,22(2):71-73.
[9] 王伊龙,孟霞,赵性泉,等.氯吡格雷用于急性非致残性脑血管事件高危人群临床研究结果解读[J].中国实用内科杂志,2014,34(2):180-182.
[10] 沈智杰,陈骁康,王英杰,等.229例急性冠脉综合征氯吡格雷抵抗患者CYP2C19基因多态性与中医证型分布的相关性[J].中国中西医结合杂志,2017,37(3):291-296.
[11] 陈昕朦,金晶,黄民,等.CYP2C19、P2Y12基因多态性与缺血性脑卒中患者氯吡格雷抵抗的相关性研究[J].中国药师,2014,17(6):885-888.
[12] 黄婷.缺血性脑血管病脑动脉狭窄支架置入治疗与中医证型研究[D].广州:广州中医药大学,2014.
[13] 张晓雷,陈俊华,郭春霞,等.丹参多酚酸盐的药理作用研究[J].世界临床药物,2013,34(5):292-297.

备注/Memo

备注/Memo:
基金名称:河南省教育厅项目(编号为18A310012) (2018-09-17收稿)
更新日期/Last Update: 2019-04-20